• Received patent acceptances in Canada, US, Europe, Australia, and Philippines
• Granted 'Improved Virucidal Formulations' patent in New Zealand
• Cash burn for June quarter was $768k, higher than expected due to pre-payments

Firebrick Pharma Ltd announced its quarterly activity for June 2026, highlighting the acceptance of two patents: one for 'Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes' in Canada and another for 'Improved Virucidal Formulations' in New Zealand. The company also noted that these patents have been accepted and/or granted in several other countries. Despite higher cash expenses of $839k, up 2% from the March quarter, due to pre-payments and one-off payments, the company managed to maintain its annual expenses at $3,078k, similar to the previous year. Sales receipts for the quarter were $66k, bringing annual sales to $227k, showing a 43% growth compared to the previous year, adjusted for a one-off receipt in June 2025.

Firebrick Pharma Ltd expects lower net operating cash flows for the coming quarter.

Firebrick Pharma Ltd is confident in its ability to secure additional funds if required, based on its past successes.